Literature DB >> 28166605

D-dimer at venous thrombosis diagnosis is associated with risk of recurrence.

E Bjøri1, H S Johnsen1, J-B Hansen1,2, S K Braekkan1,2.   

Abstract

Essentials Whether D-dimer at incident venous thromboembolism (VTE) can predict recurrence-risk is unknown. We explored this association in 454 cancer-free patients with a first lifetime VTE. A low D-dimer at first VTE diagnosis was associated with a low recurrence risk. The association was predominant in patients with deep vein thrombosis and unprovoked VTE. Click to hear Dr Cannegieter's presentation on venous thrombosis: prediction of recurrence
SUMMARY: Background Venous thromboembolism (VTE) is a common disease with a high recurrence rate. D-dimer measured after cessation of anticoagulant therapy predicts recurrence, and is used to decide on treatment prolongation. However, whether D-dimer measured at first VTE diagnosis can be used to assess recurrence-risk is unknown. Aims To investigate the association between D-dimer, measured at first VTE diagnosis and risk of recurrent VTE. Methods Information on clinical risk factors and laboratory markers were collected in 454 cancer-free patients with a first VTE. Recurrent VTEs and deaths during follow-up (1994-2012) were recorded. Results During a median follow-up of 3.9 years, 84 patients experienced a recurrent VTE. The crude recurrence rate was 1.7 (95% confidence interval [CI], 1.0-2.9) per 100 person-years in the lower quartile of D-dimer (≤ 1500 ng mL-1 ), and 4.9 (95% CI, 3.9-6.1) per 100 person-years in the upper three quartiles combined, yielding an absolute risk difference of 3.2 per 100 person-years. Patients with D-dimer ≤ 1500 ng mL-1 had 54% lower recurrence-risk than patients with D-dimer > 1500 ng mL-1 (HR, 0.46; 95% CI, 0.25-0.82). The association was particularly pronounced among patients with unprovoked events and deep vein thrombosis, showing a 66% (HR, 0.34; 95% CI, 0.15-0.74) and 68% (HR, 0.32; 95% CI, 0.14-0.71) lower recurrence risk among patients with D-dimer ≤ 1500 ng mL-1 , respectively. Conclusions A low D-dimer (≤ 1500 ng mL-1 ) measured at first VTE diagnosis was associated with a low recurrence risk, particularly among patients with DVT and unprovoked events. Our findings suggest that a clinical decision to avoid prolonged anticoagulant treatment could be considered based on low D-dimer at the time of VTE diagnosis.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  D-dimer; epidemiology; prediction; recurrence; venous thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 28166605     DOI: 10.1111/jth.13648

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Enhanced Stability of Gold Magnetic Nanoparticles with Poly(4-styrenesulfonic acid-co-maleic acid): Tailored Optical Properties for Protein Detection.

Authors:  Xiaomei Zhang; Qinlu Zhang; Ting Ma; Qian Liu; Songdi Wu; Kai Hua; Chao Zhang; Mingwei Chen; Yali Cui
Journal:  Nanoscale Res Lett       Date:  2017-09-25       Impact factor: 4.703

2.  Variable predictors of acute pulmonary embolism recurrence with duration of follow-up.

Authors:  Yi-Lan Yang; Ping Yuan; Chuan-Yu Wang; Bigyan Pudasaini; Yuan Li; Yan-Zhe Yu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Rong Jiang; Wen-Hui Wu; Jing He; Jian Guo; Ci-Jun Luo; Hong-Ling Qiu; Chang Chen; Jin-Ling Li; Jin-Ming Liu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

3.  Principal Component Analysis on Recurrent Venous Thromboembolism.

Authors:  Tiago D Martins; Joyce M Annichino-Bizzacchi; Anna V C Romano; Rubens Maciel Filho
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

4.  Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.

Authors:  Saroj Vadhan-Raj; Mairéad G McNamara; Marino Venerito; Hanno Riess; Eileen M O'Reilly; Michael J Overman; Xiao Zhou; Ujjwala Vijapurkar; Simrati Kaul; Peter Wildgoose; Alok A Khorana
Journal:  Cancer Med       Date:  2020-07-14       Impact factor: 4.452

5.  Analytical performance of a new immunoturbidimetric D-dimer assay and comparison with available assays.

Authors:  Laurie Talon; Virginie Fourneyron; Alexandre Trapani; Bruno Pereira; Thomas Sinegre; Aurélien Lebreton
Journal:  Res Pract Thromb Haemost       Date:  2022-02-06

6.  Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials.

Authors:  Luuk J J Scheres; Willem M Lijfering; Saskia Middeldorp; Yuk W Cheung; Stefano Barco; Suzanne C Cannegieter; Michiel Coppens
Journal:  Res Pract Thromb Haemost       Date:  2018-08-18

7.  Prevalence and risk factors of preoperative deep venous thrombosis in closed patella fracture: a prospective cohort study.

Authors:  Zhanchao Tan; Hongzhi Hu; Zhongzheng Wang; Yuchuan Wang; Yingze Zhang
Journal:  J Orthop Surg Res       Date:  2021-06-23       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.